ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow growth accelerates

Q1 FY2026 investing cash flow of $645K (cash outflow) rose 252.5% year over year, ahead of the +133.4% change in trailing-twelve-month investing cash flow.

Context

  • Investing cash flow amounted to 1.7% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +252.5% holds above the trailing-twelve-month pace of +133.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$645K-159.3% QoQ
Last fiscal yearDec 2025
$615K+323.6% YoY
LTMMar 2026
$153K+133.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+252.5%——
1 year+323.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
615K USD
Year-over-year change
+323.6%

Investing Cash Flow vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +133.4% is the 2nd highest of 9, against a peer median of -95.6%.
  • Investing cash flow amounts to 0.4% of revenue for CLPT, versus a peer median of 5.4%.
CLPT Competitors
Investing Cash Flow for CLPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LABStandard BioTools Inc.LTM Mar 2026$201.23M USD+236.9%—233.3%
AVNSAvanos Medical, Inc.LTM Mar 2026$59.2M USD+71.1%-23.5%8.3%
OFIXOrthofix Medical Inc.LTM Mar 2026$38.38M USD+63.7%+12.1%4.6%
CTKBCytek Biosciences, Inc.LTM Mar 2026$26.41M USD-61.0%—12.9%
SIBNSI-BONE, Inc.LTM Mar 2026$12.7M USD-175.1%—6.2%
VREXVarex Imaging CorporationLTM Apr 2026$12.2M USD-325.9%—1.4%
SNDLSNDL Inc.LTM Mar 2026CA$11.08M CAD-130.3%—1.2%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$8.14M USD-6828.9%+311.2%3.5%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$153K USD+133.4%—0.4%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
Peer median (excluding CLPT) —-95.6%+12.1%5.4%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.41M)(16.43M)(22.09M)(18.91M)(25.54M)
Depreciation & Amortization692K777K1.51M1.9M982K
Deferred Income Tax202K0000
Stock-Based Compensation2.08M4.13M6.08M6.91M8.18M
Change in Working Capital(1.68M)(4.29M)(1.4M)1.4M(9.81M)
Accounts Receivables627K(211K)(1.8M)(1.21M)(268K)
Inventory(1.71M)(4.42M)1.25M743K(103K)
Accounts Payables(762K)1.59M03.11M(7.52M)
Other Working Capital165K(1.25M)(846K)(1.24M)(1.92M)
Other Non-Cash Items425K3.78M2.18M(245K)2.27M
Operating Cash Flow(12.7M)(16.17M)(13.72M)(8.95M)(23.93M)
Capital Expenditures(168K)(253K)(717K)(275K)(522K)
Acquisitions (Net)00001.14M
Purchases of Investments0(21.59M)000
Sales of Investments012M000
Other Investing Activities009.67M00
Investing Cash Flow(168K)(10.74M)8.95M(275K)615K
Debt Repayment000(10M)48.09M
Common Stock Issued46.79M745K016.15M3.95M
Common Stock Repurchased00(210K)00
Dividends Paid00000
Other Financing Activities90K(336K)506K40K(1.86M)
Financing Cash Flow46.88M409K296K6.19M50.18M
Effect of Forex Changes00000
Net Change in Cash34.01M(26.49M)(4.48M)(3.04M)26.87M
Free Cash Flow(12.87M)(16.42M)(14.44M)(9.23M)(24.45M)

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.